Skip to content

Clinical observation and mechanism of different body surface stimulation in the treatment of mild to moderate anxiety disorder

Clinical observation and mechanism of different body surface stimulation in the treatment of mild to moderate anxiety disorder

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066916
Enrollment
Unknown
Registered
2022-12-21
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized anxiety disorder (GAD)

Interventions

Control Group:Electric pulse stimulation of routine acupuncture at Neiguan point
Experimental Group:Electric pulse stimulation by shallow needling at Neiguan point

Sponsors

AMHT Group Aerospace 731 Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1)Meet the diagnostic criteria of Western Medicine on generalized anxiety disorder; (2)Meet the diagnostic criteria of depression syndrome in traditional Chinese medicine; (3)Hamilton Anxiety Scale (HAMA) = 14, but <29; SAS score = 50, but <70. The degree of illness is mild to moderate; (4)Aged between 18 and 60 (5)No anti anxiety drugs in the last four weeks; (6)Agree to sign informed consent file.

Exclusion criteria

Exclusion criteria: Patients with one of the following criteria will be excluded: (1)Anxiety secondary to physical diseases such as hyperthyroidism, hypertension and coronary heart disease; (2)Withdrawal reaction due to excipient overdose, stopping anti anxiety drugs for less than four weeks, hypnotic sedative drugs and anti anxiety drugs; (3)There are other psychoses associated with anxiety, such as panic disorder, obsessive-compulsive disorder, phobia, hypochondria, neurasthenia, mania, depression, schizophrenia and other associated anxiety; (4)Pregnancy or breastfeeding; (5)Unstable vital signs; (6)Unconsciousness, aphasia and cognitive impairment.

Design outcomes

Primary

MeasureTime frame
Self-Rating Anxiety Scale, SAS;Heart rate variability;

Secondary

MeasureTime frame
Hamilton Anxiety Scale,HAMA;Integral evaluation of TCM Syndrome Scale;Electroencephalogram;Serum 5-HT content;Serum NE content;

Countries

China

Contacts

Public ContactZhang Yang

AMHT Group Aerospace 731 Hospital

zysunshine45@126.com13501228359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026